Skip to main content
. Author manuscript; available in PMC: 2017 Aug 15.
Published in final edited form as: Lancet Oncol. 2013 Feb 28;14(4):354–362. doi: 10.1016/S1470-2045(13)70037-8

Table 4.

Summary of best response to therapy

Best Response Tosedostat 120 mgN=38
N (%)		 Tosedostat 240 mg→120 mg N=35
N (%)		 Overall N=73
N (%)
PR or better 8 (21) 8 (23) 16 (22)
CR 0 1 (3) 1 (1)
CRp 2 (5) 4 (11) 6 (8)
MLFS 2 (5) 0 2 (3)
PR 4 (11) 3 (9) 7 (10)
SD 14 (37) 7 (20) 21 (29)
PD 6 (16) 7 (20) 13 (18)
Non-evaluable 10 (26) 13 (37) 23 (32)

CR=complete remission; CRp=complete remission with incomplete platelet recovery; MLFS=morphological leukaemia-free state; PR=partial remission; SD=stable disease; PD=progressive disease;